Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
March 04, 2024 13:00 ET
|
Oxurion NV
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...
Oxurion Announces New Strategic Orientation to De-risk and Diversify
January 22, 2024 16:02 ET
|
Oxurion NV
Leuven, BELGIUM, 22 January 2024 9:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
January 19, 2024 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
January 17, 2024 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM – January 17, 2024 – 7:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
January 12, 2024 02:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM – January 12, 2024 – 8:00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to...
Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas
December 28, 2023 15:15 ET
|
Oxurion NV
Regulated information – Inside information No bankruptcy filing Significant reduction in Working Capital costsAtlas commits to fund Oxurion’s Working Capital costs (including the Preclinical GA...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
December 01, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
November 20, 2023 01:00 ET
|
Oxurion NV
Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has Decided to Take Necessary Steps to File for...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 19, 2023 15:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special...
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year
November 16, 2023 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies,...